Published in Adv Parasitol on January 01, 2012
Mass drug administration for the control and elimination of Plasmodium vivax malaria: an ecological study from Jiangsu province, China. Malar J (2013) 1.40
Gametocyte dynamics and the role of drugs in reducing the transmission potential of Plasmodium vivax. J Infect Dis (2013) 1.03
G6PD deficiency in Latin America: systematic review on prevalence and variants. Mem Inst Oswaldo Cruz (2014) 1.01
MMV in partnership: the Eurartesim® experience. Malar J (2013) 0.97
Global Epidemiology of Plasmodium vivax. Am J Trop Med Hyg (2016) 0.93
The story of artesunate-mefloquine (ASMQ), innovative partnerships in drug development: case study. Malar J (2013) 0.88
Prevention of Malaria Resurgence in Greece through the Association of Mass Drug Administration (MDA) to Immigrants from Malaria-Endemic Regions and Standard Control Measures. PLoS Negl Trop Dis (2015) 0.81
Plasmodium vivax malaria elimination: should innovative ideas from the past be revisited? Mem Inst Oswaldo Cruz (2014) 0.81
Key Knowledge Gaps for Plasmodium vivax Control and Elimination. Am J Trop Med Hyg (2016) 0.79
Implications of Plasmodium vivax Biology for Control, Elimination, and Research. Am J Trop Med Hyg (2016) 0.75
Artemisinin combination therapy mass drug administration in a setting of low malaria endemicity: programmatic coverage and adherence during an observational study in Zanzibar. Malar J (2017) 0.75
Vivax malaria: neglected and not benign. Am J Trop Med Hyg (2007) 10.16
Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet (2010) 8.52
Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med (2008) 7.28
Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med (2008) 6.61
Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol (2010) 6.28
Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One (2009) 5.81
A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis (2012) 5.24
The pathophysiology of vivax malaria. Trends Parasitol (2009) 4.57
In vivo parasitological measures of artemisinin susceptibility. J Infect Dis (2010) 4.25
Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet (2005) 4.16
A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull World Health Organ (2008) 4.11
New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis (2009) 4.00
Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med (2005) 3.68
Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria. J Exp Med (2007) 3.13
Artemisinin combination therapy for vivax malaria. Lancet Infect Dis (2010) 3.08
The relationship between age and the manifestations of and mortality associated with severe malaria. Clin Infect Dis (2008) 3.05
Lung injury in vivax malaria: pathophysiological evidence for pulmonary vascular sequestration and posttreatment alveolar-capillary inflammation. J Infect Dis (2007) 3.02
Adverse pregnancy outcomes in an area where multidrug-resistant plasmodium vivax and Plasmodium falciparum infections are endemic. Clin Infect Dis (2008) 3.01
Evaluation of a dried blood spot HIV-1 RNA program for early infant diagnosis and viral load monitoring at rural and remote healthcare facilities. AIDS (2009) 2.89
Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. Proc Natl Acad Sci U S A (2008) 2.80
Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis (2011) 2.79
Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. Antimicrob Agents Chemother (2007) 2.73
A new NOS2 promoter polymorphism associated with increased nitric oxide production and protection from severe malaria in Tanzanian and Kenyan children. Lancet (2002) 2.69
Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms. PLoS One (2007) 2.66
A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar J (2009) 2.64
Community-acquired bacterial bloodstream infections in developing countries in south and southeast Asia: a systematic review. Lancet Infect Dis (2012) 2.58
Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob Agents Chemother (2002) 2.52
Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam. Vaccine (2006) 2.49
Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum. Malar J (2008) 2.41
Melioidosis epidemiology and risk factors from a prospective whole-population study in northern Australia. Trop Med Int Health (2004) 2.36
The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa. PLoS Negl Trop Dis (2008) 2.36
World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malar J (2007) 2.30
Likely health outcomes for untreated acute febrile illness in the tropics in decision and economic models; a Delphi survey. PLoS One (2011) 2.24
A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy. Clin Infect Dis (2012) 2.20
Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study. Lancet Infect Dis (2012) 2.18
Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis (2011) 2.16
Vivax malaria: a major cause of morbidity in early infancy. Clin Infect Dis (2009) 2.15
Severe Plasmodium knowlesi malaria in a tertiary care hospital, Sabah, Malaysia. Emerg Infect Dis (2011) 2.11
The burden of diarrhoea, shigellosis, and cholera in North Jakarta, Indonesia: findings from 24 months surveillance. BMC Infect Dis (2005) 2.10
Plasmodium vivax: clinical spectrum, risk factors and pathogenesis. Adv Parasitol (2012) 1.95
Salmonella paratyphi A rates, Asia. Emerg Infect Dis (2005) 1.94
Trend and disease burden of bacillary dysentery in China (1991-2000). Bull World Health Organ (2006) 1.93
Relationship of cell-free hemoglobin to impaired endothelial nitric oxide bioavailability and perfusion in severe falciparum malaria. J Infect Dis (2009) 1.86
Low plasma arginine concentrations in children with cerebral malaria and decreased nitric oxide production. Lancet (2003) 1.86
The anaemia of Plasmodium vivax malaria. Malar J (2012) 1.82
Diagnosing severe falciparum malaria in parasitaemic African children: a prospective evaluation of plasma PfHRP2 measurement. PLoS Med (2012) 1.82
Invasive salmonellosis among children admitted to a rural Tanzanian hospital and a comparison with previous studies. PLoS One (2010) 1.81
The case for reactive mass oral cholera vaccinations. PLoS Negl Trop Dis (2011) 1.70
Simplified antimalarial therapeutic monitoring: using the day-7 drug level? Trends Parasitol (2008) 1.70
Inferred relatedness and heritability in malaria parasites. Proc Biol Sci (2010) 1.69
Plasmodium falciparum gametocyte dynamics in areas of different malaria endemicity. Malar J (2008) 1.69
Increasing incidence of Plasmodium knowlesi malaria following control of P. falciparum and P. vivax Malaria in Sabah, Malaysia. PLoS Negl Trop Dis (2013) 1.68
Limitations of microscopy to differentiate Plasmodium species in a region co-endemic for Plasmodium falciparum, Plasmodium vivax and Plasmodium knowlesi. Malar J (2013) 1.66
Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. Clin Infect Dis (2011) 1.64
Is plasma arginine concentration decreased in patients with sepsis? A systematic review and meta-analysis. Crit Care Med (2011) 1.63
Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J (2012) 1.61
Cardiovascular disease in the developing world: prevalences, patterns, and the potential of early disease detection. J Am Coll Cardiol (2012) 1.59
A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS One (2008) 1.57
A simple, valid, numerical score for grading chest x-ray severity in adult smear-positive pulmonary tuberculosis. Thorax (2010) 1.55
Plasmodium vivax trophozoites insensitive to chloroquine. Malar J (2008) 1.54
Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa. Bull World Health Organ (2011) 1.54
A simple score to predict the outcome of severe malaria in adults. Clin Infect Dis (2010) 1.54
Field evaluation of a rapid immunochromatographic dipstick test for the diagnosis of cholera in a high-risk population. BMC Infect Dis (2006) 1.53
Factors associated with reported diarrhoea episodes and treatment-seeking in an urban slum of Kolkata, India. J Health Popul Nutr (2004) 1.53
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg (2014) 1.51
Feasibility of a mass vaccination campaign using a two-dose oral cholera vaccine in an urban cholera-endemic setting in Mozambique. Vaccine (2005) 1.50
Intrahost selection of Plasmodium falciparum pfmdr1 alleles after antimalarial treatment on the northwestern border of Thailand. J Infect Dis (2006) 1.49
Defining falciparum-malaria-attributable severe febrile illness in moderate-to-high transmission settings on the basis of plasma PfHRP2 concentration. J Infect Dis (2012) 1.49
Outcomes of patients with melioidosis treated with meropenem. Antimicrob Agents Chemother (2004) 1.48
Deaths due to Plasmodium knowlesi malaria in Sabah, Malaysia: association with reporting as Plasmodium malariae and delayed parenteral artesunate. Malar J (2012) 1.47
The global public health significance of Plasmodium vivax. Adv Parasitol (2012) 1.46
Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria. PLoS Pathog (2009) 1.46
Pandemic serovars (O3:K6 and O4:K68) of Vibrio parahaemolyticus associated with diarrhea in Mozambique: spread of the pandemic into the African continent. J Clin Microbiol (2005) 1.46
Granzyme B expression by CD8+ T cells is required for the development of experimental cerebral malaria. J Immunol (2011) 1.46
Estimating the burden of shigellosis in Thailand: 36-month population-based surveillance study. Bull World Health Organ (2005) 1.45
Multilocus sequence typing (MLST) analysis of Vibrio cholerae O1 El Tor isolates from Mozambique that harbour the classical CTX prophage. J Med Microbiol (2006) 1.44
Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis. Clin Infect Dis (2003) 1.44
Reducing stunting among children: the potential contribution of diagnostics. Nature (2006) 1.44
Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine (2006) 1.43
Plasmodium knowlesi malaria in children. Emerg Infect Dis (2011) 1.42
Eosinophils in severe sepsis in northern australia: do the usual rules apply in the tropics? Crit Care Med (2013) 1.42
Pneumonia risk stratification in tropical Australia: does the SMART-COP score apply? Med J Aust (2010) 1.41
Epidemiology of Plasmodium knowlesi malaria in north-east Sabah, Malaysia: family clusters and wide age distribution. Malar J (2012) 1.40
High deformability of Plasmodium vivax-infected red blood cells under microfluidic conditions. J Infect Dis (2009) 1.40
Malaria tolerance--for whom the cell tolls? Trends Parasitol (2006) 1.40
Paperless registration during survey enumerations and large oral cholera mass vaccination in Zanzibar, the United Republic of Tanzania. Bull World Health Organ (2010) 1.38
Decreasing incidence of severe malaria and community-acquired bacteraemia among hospitalized children in Muheza, north-eastern Tanzania, 2006-2010. Malar J (2011) 1.37